23 November 2022 - TAK-003 is being evaluated for the prevention of Dengue disease caused by any Dengue virus serotype in individuals 4 years through 60 years of age.
Takeda today announced that the US FDA has accepted and granted priority review of the biologics license application for TAK-003, the company’s investigational dengue vaccine candidate.